Robeco Institutional Asset Management’s Neurocrine Biosciences NBIX Stock Holding History
| Quarter | Market Value | Status | Shares |
Shares Change % | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | $1.9M | Sell |
15,098
-1,122
| -7% | -$141K | ﹤0.01% | 696 |
|
|
2025
Q1 | $1.79M | Buy |
16,220
+1,586
| +11% | +$175K | ﹤0.01% | 724 |
|
|
2024
Q4 | $2M | Sell |
14,634
-372,648
| -96% | -$50.9M | ﹤0.01% | 700 |
|
|
2024
Q3 | $44.6M | Buy |
387,282
+53,301
| +16% | +$6.14M | 0.09% | 215 |
|
|
2024
Q2 | $46M | Buy |
333,981
+23,756
| +8% | +$3.27M | 0.1% | 189 |
|
|
2024
Q1 | $42.8M | Buy |
310,225
+132,526
| +75% | +$18.3M | 0.09% | 212 |
|
|
2023
Q4 | $23.4M | Buy |
177,699
+23,632
| +15% | +$3.11M | 0.06% | 306 |
|
|
2023
Q3 | $17.3M | Sell |
154,067
-1,096
| -0.7% | -$123K | 0.05% | 343 |
|
|
2023
Q2 | $14.6M | Sell |
155,163
-7,276
| -4% | -$686K | 0.04% | 370 |
|
|
2023
Q1 | $16.4M | Sell |
162,439
-25,765
| -14% | -$2.61M | 0.04% | 351 |
|
|
2022
Q4 | $22.5M | Buy |
188,204
+123,826
| +192% | +$14.8M | 0.06% | 291 |
|
|
2022
Q3 | $6.84M | Buy |
64,378
+55,548
| +629% | +$5.9M | 0.02% | 469 |
|
|
2022
Q2 | $861K | Buy |
8,830
+8,220
| +1,348% | +$802K | ﹤0.01% | 716 |
|
|
2022
Q1 | $57K | Sell |
610
-2,838
| -82% | -$265K | ﹤0.01% | 898 |
|
|
2021
Q4 | $294K | Buy |
3,448
+66
| +2% | +$5.63K | ﹤0.01% | 810 |
|
|
2021
Q3 | $324K | Hold |
3,382
| – | – | ﹤0.01% | 808 |
|
|
2021
Q2 | $329K | Hold |
3,382
| – | – | ﹤0.01% | 845 |
|
|
2021
Q1 | $329K | Sell |
3,382
-709
| -17% | -$69K | ﹤0.01% | 827 |
|
|
2020
Q4 | $392K | Hold |
4,091
| – | – | ﹤0.01% | 801 |
|
|
2020
Q3 | $393K | Buy |
4,091
+3,964
| +3,121% | +$381K | ﹤0.01% | 778 |
|
|
2020
Q2 | $15K | Sell |
127
-3,229
| -96% | -$381K | ﹤0.01% | 959 |
|
|
2020
Q1 | $290K | Buy |
3,356
+2,871
| +592% | +$248K | ﹤0.01% | 859 |
|
|
2019
Q4 | $52K | Buy |
+485
| New | +$52K | ﹤0.01% | 944 |
|